Baxter International Inc. (NYSE:BAX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Effective May1, 2017, Giuseppe Accogli, formerly the Corporate
Vice President and President, Renal of Baxter International Inc.
(the Company), changed roles and has assumed the role of Senior
Vice President and President, Global Businesses. Brik Eyre,
formerly the Corporate Vice President and President, Hospital
Products of the Company, changed roles and has assumed the role
of Senior Vice President and President, Americas effective as of
the same date. These changes were made in connection with the
Companys continuing portfolio management and transformation
efforts.
| Item5.07 |
Submission of Matters to a Vote of Security Holders |
On May2, 2017, the Company held its annual meeting of
stockholders. Of the 541,957,424 shares outstanding and entitled
to vote, 463,286,811 shares were represented at the meeting,
constituting a quorum of approximately 85.5%. The following is a
summary of the matters voted on at the meeting.
| (a) | The eight nominees for director were elected as follows: |
|
Nominee |
For | Against | Abstain | BrokerNon- Votes | ||||
|
Jos (Joe) Almeida |
384,103,720 | 21,180,292 | 5,904,089 | 52,098,710 | ||||
|
Thomas F. Chen |
400,745,186 | 9,978,717 | 464,198 | 52,098,710 | ||||
|
John D. Forsyth |
393,067,950 | 17,639,528 | 480,623 | 52,098,710 | ||||
|
Munib Islam |
392,787,890 | 17,887,002 | 513,209 | 52,098,710 | ||||
|
Michael F. Mahoney |
400,763,563 | 9,941,483 | 483,055 | 52,098,710 | ||||
|
Carole J. Shapazian |
399,898,863 | 10,840,154 | 449,084 | 52,098,710 | ||||
|
Thomas T. Stallkamp |
392,184,503 | 18,527,024 | 476,574 | 52,098,710 | ||||
|
Albert P.L. Stroucken |
396,538,427 | 14,174,655 | 475,019 | 52,098,710 |
| (b) |
By the following vote, stockholders approved, on an advisory basis, the 2016 compensation paid to the Companys named executive officers: |
|
For |
Against |
Abstain |
BrokerNon-Votes |
|||
|
397,027,576 |
13,170,037 | 990,488 | 52,098,710 |
| (c) |
By the following vote, shareholders recommended, on an advisory basis, to hold an advisory vote on executive compensation on an annual basis: |
|
Every Year |
EveryTwoYears |
EveryThreeYears |
Abstain |
BrokerNon-Votes |
||||
|
362,847,120 |
1,936,480 | 45,599,733 | 804,768 | 52,098,710 |
The Company will include an advisory shareholder vote on
executive compensation in its proxy materials every year until
the next required advisory vote on the frequency of shareholder
votes on executive compensation.
| (d) |
The appointment of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for 2017 was ratified by the following vote: |
|
For |
Against |
Abstain |
||
|
451,261,925 |
9,277,776 | 2,747,110 |
| (e) |
By the following vote, stockholders did not approve the stockholder proposal relating to amending the proxy access bylaw to increase the stockholder aggregation cap: |
|
For |
Against |
Abstain |
BrokerNon-Votes |
|||
|
115,315,542 |
293,964,705 | 1,907,854 | 52,098,710 |
About Baxter International Inc. (NYSE:BAX)
Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries. Baxter International Inc. (NYSE:BAX) Recent Trading Information
Baxter International Inc. (NYSE:BAX) closed its last trading session up +0.05 at 55.96 with 2,838,739 shares trading hands.